ARQ Wealth Advisors LLC Grows Stock Holdings in Becton, Dickinson and Company $BDX

ARQ Wealth Advisors LLC raised its holdings in shares of Becton, Dickinson and Company (NYSE:BDX) by 438.3% during the first quarter, HoldingsChannel reports. The fund owned 16,525 shares of the medical instruments supplier’s stock after purchasing an additional 13,455 shares during the quarter. ARQ Wealth Advisors LLC’s holdings in Becton, Dickinson and Company were worth $2,598,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds also recently made changes to their positions in BDX. Brighton Jones LLC grew its stake in Becton, Dickinson and Company by 98.2% during the fourth quarter. Brighton Jones LLC now owns 1,770 shares of the medical instruments supplier’s stock valued at $401,000 after acquiring an additional 877 shares in the last quarter. Graybill Wealth Management LTD. boosted its holdings in Becton, Dickinson and Company by 47.3% in the 3rd quarter. Graybill Wealth Management LTD. now owns 27,592 shares of the medical instruments supplier’s stock valued at $5,164,000 after purchasing an additional 8,859 shares during the period. Danske Bank A S purchased a new position in shares of Becton, Dickinson and Company during the 3rd quarter valued at $34,596,000. Cinctive Capital Management LP grew its position in shares of Becton, Dickinson and Company by 71.6% during the 3rd quarter. Cinctive Capital Management LP now owns 16,847 shares of the medical instruments supplier’s stock valued at $3,153,000 after purchasing an additional 7,028 shares in the last quarter. Finally, CIBC Bancorp USA Inc. bought a new position in shares of Becton, Dickinson and Company in the third quarter worth $7,401,000. 86.97% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several equities research analysts recently issued reports on BDX shares. Weiss Ratings lowered Becton, Dickinson and Company from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Monday, May 11th. Stifel Nicolaus lowered their price target on Becton, Dickinson and Company from $215.00 to $175.00 in a report on Thursday, May 7th. Bank of America dropped their price target on Becton, Dickinson and Company from $177.00 to $170.00 in a research report on Friday, June 12th. TD Cowen decreased their price objective on shares of Becton, Dickinson and Company from $189.00 to $163.00 and set a “hold” rating on the stock in a research report on Monday, May 4th. Finally, Royal Bank Of Canada set a $175.00 target price on shares of Becton, Dickinson and Company in a research report on Tuesday, April 14th. Seven investment analysts have rated the stock with a Buy rating, eight have given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Becton, Dickinson and Company has a consensus rating of “Hold” and an average target price of $180.29.

Becton, Dickinson and Company Trading Up 0.9%

Shares of BDX traded up $1.31 during trading hours on Friday, hitting $152.16. The company had a trading volume of 1,048,159 shares, compared to its average volume of 2,698,424. Becton, Dickinson and Company has a 52-week low of $127.59 and a 52-week high of $187.35. The company has a quick ratio of 0.55, a current ratio of 0.94 and a debt-to-equity ratio of 0.62. The stock’s 50 day moving average price is $148.25 and its 200 day moving average price is $167.81. The firm has a market cap of $41.93 billion, a P/E ratio of 38.52, a P/E/G ratio of 10.75 and a beta of 0.21.

Becton, Dickinson and Company (NYSE:BDX) last issued its earnings results on Thursday, May 7th. The medical instruments supplier reported $2.90 earnings per share for the quarter, beating the consensus estimate of $2.77 by $0.13. Becton, Dickinson and Company had a return on equity of 15.37% and a net margin of 5.33%.The company had revenue of $4.71 billion during the quarter, compared to analysts’ expectations of $4.67 billion. During the same period in the prior year, the business posted $3.35 EPS. Becton, Dickinson and Company’s quarterly revenue was up 5.2% compared to the same quarter last year. Becton, Dickinson and Company has set its FY 2026 guidance at 12.520-12.720 EPS. On average, research analysts predict that Becton, Dickinson and Company will post 12.62 EPS for the current year.

Becton, Dickinson and Company Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Tuesday, June 30th. Stockholders of record on Tuesday, June 9th were issued a $1.05 dividend. The ex-dividend date was Tuesday, June 9th. This represents a $4.20 annualized dividend and a dividend yield of 2.8%. Becton, Dickinson and Company’s dividend payout ratio (DPR) is currently 106.33%.

Insider Buying and Selling at Becton, Dickinson and Company

In related news, EVP Michael David Garrison sold 1,100 shares of Becton, Dickinson and Company stock in a transaction on Wednesday, June 24th. The shares were sold at an average price of $145.66, for a total value of $160,226.00. Following the transaction, the executive vice president directly owned 13,172 shares of the company’s stock, valued at $1,918,633.52. The trade was a 7.71% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Thomas E. Polen, Jr. sold 2,764 shares of the stock in a transaction on Monday, June 1st. The shares were sold at an average price of $146.35, for a total transaction of $404,511.40. Following the sale, the chief executive officer directly owned 110,163 shares of the company’s stock, valued at $16,122,355.05. The trade was a 2.45% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders sold 5,188 shares of company stock worth $765,120. 0.40% of the stock is owned by insiders.

About Becton, Dickinson and Company

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.